The ANGEL1 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of A-549 cells carrying a targeted disruption of the ANGEL1 gene. This polyclonal knockout cell mixture provides a heterogeneous loss-of-function model, capturing diverse editing outcomes and enabling functional studies at the population level without the biases of single-cell cloning. The use of polyclonal knockout cells is well-suited for experiments that require assessment of overall gene function in a near-physiological context.
The parental A-549 cell line is a human lung adenocarcinoma model originally derived from a 58-year-old male. It exhibits an adherent epithelial morphology and is widely employed in lung cancer research and drug screening. A-549 cells retain characteristics of alveolar type II epithelial cells, making them a relevant and well-characterized system for investigating RNA decay pathways in the context of lung adenocarcinoma biology.
ANGEL1 encodes a 3??-5?? exoribonuclease that localizes to cytoplasmic processing bodies (P-bodies), dynamic ribonucleoprotein granules central to mRNA decay. Within P-bodies, ANGEL1 interacts with decapping activators DCP1A and EDC4, linking its exoribonucleolytic activity to cap removal. It functions in concert with the 5??-3?? exonuclease XRN1 and the LSM1-7 complex to mediate complete mRNA substrate degradation. Although upstream regulators remain poorly characterized, the stable association of ANGEL1 with these core P-body components underscores its pivotal role in the mRNA surveillance network.
Introducing an ANGEL1 knockout in the A-549 adenocarcinoma background allows focused dissection of how P-body-mediated RNA decay influences cancer cell phenotypes. Given that ANGEL1 is broadly expressed in malignant tissues, its loss may alter the stability of transcripts involved in cell proliferation, apoptosis, or drug sensitivity. This model thus enables research into post-transcriptional gene regulation that could impact lung tumor behavior, offering a platform to identify novel vulnerabilities in cancer cells driven by altered RNA metabolism.
This ANGEL1 polyclonal knockout cell population supports a diverse range of applications, including functional studies of RNA metabolism, mechanistic investigations of P-body dynamics, and drug response assays in lung adenocarcinoma models. It is compatible with standard techniques such as RT-qPCR, western blotting, RNA stability assays, co-immunoprecipitation, immunofluorescence, and transcriptome-wide RNA-seq. By employing these methods, researchers can systematically explore the molecular consequences of ANGEL1 loss. For detailed product specifications or technical assistance, please contact Ascent Research.
